Biomaterials Market Report 2026

The biomaterials market size has grown rapidly in recent years. It will grow from $151.47 billion in 2025 to $172.54 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to growth in orthopedic and dental implant procedures, rising prevalence of cardiovascular diseases, increased healthcare infrastructure development, advancements in polymer and metal processing technologies, growing adoption of medical implants.

The biomaterials market size is expected to see rapid growth in the next few years. It will grow to $284.44 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to aging global population, increasing demand for regenerative medicine, advancements in 3d printing of biomaterials, rising investment in biomedical research, expanding applications in neurological and wound healing treatments. Major trends in the forecast period include rising demand for biocompatible and bioactive materials, growing adoption of biodegradable biomaterials, increasing use of biomaterials in tissue engineering, expansion of advanced implantable medical devices, rising focus on customized and patient-specific biomaterials.

The rising healthcare spending is expected to drive the growth of the biomaterials market. Healthcare spending refers to the total financial resources allocated for medical services, treatments, and healthcare infrastructure over a specific period, typically at a national or institutional level. A portion of this spending is directed toward the research, development, procurement, adoption, and regulatory compliance of biomaterials. For example, in 2025, according to the American Medical Association (AMA), a U.S.-based professional association, the United States spent a total of $4.86 trillion, or $14,570 per capita, on healthcare in 2023. This represents a 7.5% increase from the previous year, reflecting a significant rise compared to the 4.6% growth seen in 2022. As healthcare spending increases, it will contribute to the growth of the biomaterials market.

Major companies operating in the biomaterials market focus on technological advancements, such as the designed enzymatic biomaterials (DEB) technology platform, to deliver sustainable biopolymers and gain a competitive advantage. The enzymatic biomaterials (DEB) technology platform involves the use of enzymes to design and modify materials for various applications, including drug delivery, tissue engineering, and diagnostics. For instance, in June 2023, International Flavors & Fragrances Inc., a US-based producer of flavors, fragrances, and cosmetic actives, launched the enzymatic biomaterials technology platform for the development of biobased materials at scale. Designed to deliver meaningful sustainability benefits with performance comparable to or superior to fossil-based materials, DEB technology helps to address growing preferences for environmentally friendly, high-performance biopolymers. The technology platform allows producers to fulfill regulatory changes and increasing consumer demand by replacing traditional fossil-based synthetic polymers.

In October 2024, RTI Surgical (RTI), a US-based medical equipment manufacturing company, acquired Collagen Solutions plc for an undisclosed amount. The objective of RTI Surgical's acquisition of Collagen Solutions is to broaden its soft tissue portfolio and improve its capabilities in the regenerative medicine sector. Collagen Solutions plc is a US-based supplier, developer, and manufacturer of medical-grade collagen, tissues, and other biomaterials for use in regenerative medicine, medical devices, and research.

Major companies operating in the biomaterials market report are Corbion N V, Evonik Industries AG, Heraeus Medical Components LLC, Berkeley Advanced Biomaterials Inc., Zimmer Biomet Holdings Inc., DSM Biomedical BV, PolyNovo Limited, Baxter International Inc., Stryker Corporation, Collagen Solutions plc, Invibio Ltd., Aap Implantate AG, Cam Bioceramics BV, CeramTec GmbH, CoorsTek Medical LLC, CryoLife Inc., Cerapedics Inc., Surmodics Inc., Secant Group LLC, GELITA AG, Kyocera Corporation, Wright Medical Group NV, KLS Martin Group GmbH & Co KG, Meccellis Biotechnology Co Ltd., Bio-on SpA, Coloplast A/S, Collagen Matrix Inc., IntrinsiQ Materials Inc., PolyActiva Pty Ltd.

North America was the largest region in the biomaterials market in 2025. The regions covered in the biomaterials market are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomaterials market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomaterials market consists of sales of metals, polymers, and composites. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.